NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

NeoGenomics Inc.

NeoGenomics ( ($NEO) ) has issued an update. On May 21, 2026, NeoGenomics, Inc. held its annual meeting of stockholders, where investors approved a...

NeoGenomics Shareholders Approve Expanded Equity Incentive Plan

NeoGenomics Inc. (($NEO)) has held its Q1 earnings call. Read on for the main highlights of the call. NeoGenomics Inc.’s latest earnings call struc...

NeoGenomics Earnings Call Highlights NGS-Driven Momentum

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on NeoVolta (NEOV) and Mobile Infrastructure Co...

Analysts Offer Insights on Industrial Goods Companies: NeoVolta (NEOV) and Mobile Infrastructure Corp (BEEP)

Stranger Holdings ( ($GB:NEO) ) has shared an update. Neo Energy Metals reported that all resolutions at its latest annual general meeting were pas...

Neo Energy Metals gains strong AGM backing as it advances South African uranium plans

The latest announcement is out from NeoVolta ( ($NEOV) ). On May 14, 2026, NeoVolta appointed veteran clean-energy finance executive Jing Nealis as...

NeoVolta Appoints New CFO to Support Growth Strategy

Analysts are intrested in these 5 stocks: ( ($NEO) ), ( ($SPOT) ), ( ($OPK) ), ( ($APPN) ) and ( ($META) ). Here is a breakdown of their recent


NeoGenomics, Spotify, Opko, Appian, Meta Trending With Analysts

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NeoGenomics (NEO), CG Oncology, Inc. (CGON) and Icon (ICLR). NeoG...

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), CG Oncology, Inc. (CGON) and Icon (ICLR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NeoGenomics (NEO) and Wave Life Sciences (WVE) with ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals (TLPPF) and NeoGenomics (NEO) ...

Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), NeoGenomics (NEO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medtronic (MDT), Neogen (NEOG) and Community Healt...

Market Cap	$1.10B	P/E Ratio	N/A
52W High	$13.74	52W Low	$4.72
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	10.2%	52W Position	50.1%
Overall Score	49	Value Score	60
Quality Score	47	Technical Score	41

EPS Current Est	$-0.15	EPS Next Est	$0.03
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NEO	$9.24	+0.12%	407.20K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NEO	$9.24	+0.1%	407.20K
3
4
5
6

NEO

NEO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get NeoGenomics Inc. Data in Excel

Get NeoGenomics Inc. Data in Excel